{"id":"W3131242205","doi":"10.1016/j.cllc.2021.02.010","title":"Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme; Bayer Fund; Ipsen Biopharmaceuticals; Merck KGaA; Prince of Songkla University; F. Hoffmann-La Roche; AbbVie; Meso Scale Diagnostics; Sanofi; Roche; EMD Serono; Novartis; MedImmune; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Durvalumab; Tremelimumab; Medicine; Hazard ratio; Internal medicine; Chemotherapy; Oncology; Lung cancer; Confidence interval; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002126856,0.0003760648,0.001304541,0.0001604821,0.0001533439,0.000462173,0.0004339189,0.0004424822,0.001616474],"category_scores_gemma":[0.002075574,0.0001661596,0.001359357,0.0002073091,0.000298647,0.0004393317,0.0002249449,0.001034062,0.0001660454],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005868596,"about_ca_system_score_gemma":0.0005908264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003762026,"about_ca_topic_score_gemma":0.0008111974,"domain_scores_codex":[0.999286,0.0003808042,0.00005987015,0.0001024774,0.0001032347,0.00006750797],"domain_scores_gemma":[0.9984311,0.0004824826,0.0006023262,0.00007226752,0.0000792776,0.0003324015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8678565,0.006815925,0.02465061,0.0009346619,0.004368678,0.00005441727,0.0001065416,0.002931726,0.005623822,0.0001207909,0.001365541,0.08517086],"study_design_scores_gemma":[0.2468814,0.5605045,0.1756159,0.0001141986,0.005042132,0.0003139044,0.00008253736,0.005383773,0.004065881,0.0002961965,0.00165039,0.00004923514],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975642,0.001384669,0.0001045095,0.0000866012,0.00003419323,0.0001251628,0.0002793807,0.0000110925,0.0004101496],"genre_scores_gemma":[0.9984605,0.0003769068,0.0002001078,0.000111446,0.00004610403,0.0002287086,0.0003799457,0.000002242826,0.0001941491],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002126856,"threshold_uncertainty_score":0.01124805,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05276557928474587,"score_gpt":0.3996062283725302,"score_spread":0.3468406490877843,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}